MDB Capital Holdings, LLC (NASDAQ:MDBH – Get Free Report) insider Christopher Marlett bought 4,400 shares of MDB Capital stock in a transaction that occurred on Tuesday, December 30th. The stock was bought at an average price of $3.18 per share, for a total transaction of $13,992.00. Following the completion of the acquisition, the insider directly owned 162,333 shares of the company’s stock, valued at $516,218.94. The trade was a 2.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
MDB Capital Trading Up 0.3%
MDBH stock traded up $0.01 during midday trading on Wednesday, hitting $3.26. The stock had a trading volume of 20,749 shares, compared to its average volume of 9,823. The firm has a market cap of $33.06 million, a P/E ratio of 3.51 and a beta of 1.08. The business has a fifty day moving average price of $3.54 and a two-hundred day moving average price of $3.79. MDB Capital Holdings, LLC has a 1-year low of $3.11 and a 1-year high of $7.98.
MDB Capital (NASDAQ:MDBH – Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.46) earnings per share for the quarter. The business had revenue of $1.42 million during the quarter.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of MDB Capital in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on MDB Capital
About MDB Capital
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.
Featured Stories
- Five stocks we like better than MDB Capital
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for MDB Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDB Capital and related companies with MarketBeat.com's FREE daily email newsletter.
